Last reviewed · How we verify
APAC
At a glance
| Generic name | APAC |
|---|---|
| Sponsor | Aplagon Oy |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effective Translation of Endovascular Thrombectomy Trials Into Real-world Practice in the Asia-Pacific
- A PMCF Study in Patients With Thoracoabdominal Aortic Aneurysms Treated With E-nside TAAA Multibranch Stent Graft System (INNER-B-APAC)
- Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia (PHASE2)
- STOP HCC-GAAD-APAC-Thailand (NA)
- Defeat Rare Disease in Asia and Pacific (APAC) DRDA - Haemophilia
- Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography) (EARLY_PHASE1)
- A Study of High Risk Localized Prostate Cancer Participants Treated With Radical Prostatectomy and Perioperative Hormonal Therapy
- Persistent Atrial Fibrillation (AF) APAC (Asia Pacific) Observational Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APAC CI brief — competitive landscape report
- APAC updates RSS · CI watch RSS
- Aplagon Oy portfolio CI